---
reference_id: "PMID:34081848"
title: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
authors:
- Tutt ANJ
- Garber JE
- Kaufman B
- Viale G
- Fumagalli D
- Rastogi P
- Gelber RD
- de Azambuja E
- Fielding A
- Balmaña J
- Domchek SM
- Gelmon KA
- Hollingsworth SJ
- Korde LA
- Linderholm B
- Bandos H
- Senkus E
- Suga JM
- Shao Z
- Pippas AW
- Nowecki Z
- Huzarski T
- Ganz PA
- Lucas PC
- Baker N
- Loibl S
- McConnell R
- Piccart M
- Schmutzler R
- Steger GG
- Costantino JP
- Arahmani A
- Wolmark N
- McFadden E
- Karantza V
- Lakhani SR
- Yothers G
- Campbell C
- Geyer CE Jr
- OlympiA Clinical Trial Steering Committee and Investigators
journal: N Engl J Med
year: '2021'
doi: 10.1056/NEJMoa2105215
content_type: abstract_only
---

# Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
**Authors:** Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr, OlympiA Clinical Trial Steering Committee and Investigators
**Journal:** N Engl J Med (2021)
**DOI:** [10.1056/NEJMoa2105215](https://doi.org/10.1056/NEJMoa2105215)

## Content

1. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 
2021 Jun 3.

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

Tutt ANJ(1), Garber JE(1), Kaufman B(1), Viale G(1), Fumagalli D(1), Rastogi 
P(1), Gelber RD(1), de Azambuja E(1), Fielding A(1), Balmaña J(1), Domchek 
SM(1), Gelmon KA(1), Hollingsworth SJ(1), Korde LA(1), Linderholm B(1), Bandos 
H(1), Senkus E(1), Suga JM(1), Shao Z(1), Pippas AW(1), Nowecki Z(1), Huzarski 
T(1), Ganz PA(1), Lucas PC(1), Baker N(1), Loibl S(1), McConnell R(1), Piccart 
M(1), Schmutzler R(1), Steger GG(1), Costantino JP(1), Arahmani A(1), Wolmark 
N(1), McFadden E(1), Karantza V(1), Lakhani SR(1), Yothers G(1), Campbell C(1), 
Geyer CE Jr(1); OlympiA Clinical Trial Steering Committee and Investigators.

Collaborators: Tutt A, Geyer C, Garber J, Kaufman B, Campbell C, Yothers G, 
Baker N, McConnell R, Piccart M, Gelber RD, Rastogi P, Hollingsworth S, Fielding 
A, Korde L, Viale G, Lakhani S, Lucas P, Rossi G, Singer C, Stickeler E, 
Phillips KA, Jager A, Senkus E, Arnedos M, Fein L, De Dueñas EM, Marmé F, 
Zoppoli G, Jóhannsson Ó, Gianni L, Bliss J, Toi M, Eisen A, Armstrong A, Loman 
N, Balmaña J, Janni W, Bergh J, Liu TW, Delaloge S, Ford J, Sharma P, Traina T, 
Im SA, Friedman S, Spanic T, Domchek S, Schmutzler R, Gelmon K, Steger GG, 
Linderholm B, Loibl S, Zhmin S, Murray K, Aktan G, Mcfadden E, Andriienko O, Cui 
K, Karantza V, Tryfonidis K, Arahmani A, de Azambuja E, De Vos L, Dent R, 
Foulkes W, Olah E, Orr M, Hayes D, Richardson A, Lord C, Jonkers J, Hoejimakers 
J, Barrett C, Harrington E, Lukashchuk N, Barlow WE, Berliner N, Eisenhauer E, 
Olsson H, Swain S, Sevelda P, Haslbauer F, Penzinger M, Öhler L, Tinchon C, 
Greil R, Heibl S, Bartsch R, Wette V, Pasterk C, Helfgott R, Pristauz-Telsnigg 
G, Stöger H, Weltermann A, Egle D, Thiel I, Fuchs D, Rumpold H, Strasser-Weippl 
K, Rautenberg B, Müller V, Schmidt M, Paepke S, Aydogdu M, Thomssen C, Rom J, 
Mau C, Fasching P, Göhring UJ, Kühn T, Noeding S, Kümmel S, Hackmann J, Joshi A, 
Dewar J, Friedlander M, Antill Y, Woodward N, Abdi E, Tiley S, George M, Boadle 
D, Goodwin A, van der Westhuizen A, Kannourakis G, Murray N, McCarthy N, Kroep 
J, de Boer M, Heijns J, Erdkamp F, Bakker S, Sonke G, Sami A, Mackey J, Prady C, 
Desbiens C, Patocskai E, Ferrario C, Bordeleau L, Chalchal H, Niraula S, Wolf I, 
Senkus E, Duhoux F, d'Hondt R, Luce S, t'Kint de Roodenbeke D, Papadimitriou K, 
Borms M, Quaghebeur C, Jacot W, Brain E, Venat-Bouvet L, Lortholary A, Nowecki 
Z, Cardoso F, Hayward R, Bella S, Fernández Lazzaro M, Pilnik N, Blajman C, 
Lerzo G, Varela M, Zarba JJ, Kaen D, Constanzo MV, Tio J, Siggelkow W, Jackisch 
C, Grischke EM, Zahm D, Tato-Varela S, Schmatloch S, Klare P, Stefek A, Rhiem K, 
Hoffmann O, Deryal M, Gröll I, Ledwon P, Uleer C, Chemnitz K, Krabisch P, 
Potenberg J, Darsow M, Park-Simon TW, Höffkes HG, Emde TO, Graffunder G, Tomé O, 
Forstmeyer D, Terhaag J, Salat C, Kast K, Weniger S, Schreiber C, Heinrich B, 
Südstadt K, Dieterich M, Wüllner MP, Conejero RA, García Sáenz JÁ, Calvo 
Martinez L, Arcusa Lanza A, Morales Murillo S, Henao Carrasco F, Blanch Tormo S, 
Álvarez López I, Ignacio Delgado Mingorance J, Álvarez Gomez E, Santisteban M, 
Cruz Jurado J, Quiroga V, Ruiz Borrego M, Martínez de Dueñas E, Alés Martínez 
JE, De la Haba J, Martínez Jañez N, Rodríguez Lescure Á, Antón Torres A, Llort 
Crusades G, González-Santiago S, Marquez Aragones A, Ortega AL, Barnadas Molins 
A, Chacón López-Muñiz JI, Jiménez MM, Santaballa Bertrán AL, Rodríguez C, 
González Cortijo L, Cretella E, Cortesi L, Ruggeri EM, Verusio C, Gori S, 
Bonetti A, Mosconi AM, Johannsson O, Jerusalem G, Neven P, Nagy T, Pinotti G, 
Colleoni M, Bernardo A, Bucci E, Biganzoli L, Dedes K, Novak U, Zaman K, 
Braybrooke J, Winter M, Rea D, Kelleher M, Barrett S, Chan S, Hickish T, Hurwitz 
J, Conibear J, Jegannathen A, Parton M, Allerton R, Borley A, Copson E, Levitt 
N, Abraham J, Perren T, Roylance R, Ishida K, Toyama T, Masuda N, Watanabe J, 
Tokunaga E, Kinoshita T, Rai Y, Takada M, Yanagita Y, Nakamura R, Nakayama T, 
Naoi Y, Iwata H, Nakamura S, Takahashi M, Aogi K, Tsugawa K, Mukai H, Takano T, 
Osaki A, Sato N, Yamauchi H, Tokuda Y, Ito M, Sugimoto T, Carlson JW, Bahadur 
SW, Ganz PA, Lu MJ, Mita MM, Mortimer JE, Polikoff JA, D'Andre SD, Telli ML, 
Seaward SA, Fehrenbacher L, Puthillath A, Feusner JH, Bobolis KA, Eisenberg PD, 
Borges VF, Urquhart AT, Hofstatter EW, McCarron EC, Grubbs SS, Deveras RAE, 
Mahtani RL, Paplomata E, Sumrall BT, Jones CF, Ofori SN, Sumida KNM, Thomas A, 
Wilbur DW, Singh J, Spector DM, Stella PJ, Marchello BT, Merkel DE, Lo SS, 
Khosla PG, Cristofanilli M, Hoskins KF, Cobleigh MA, Lambiase EA, Hahn OM, Oliff 
IA, Faller BA, Wade JL, Burhani ND, Gil A, Einhorn HE, Vita Storniolo AM, Chang 
BK, Kalra M, Robin EL, Ansari B, Dakhil SR, Deming RL, Cole JT, Hanson DS, Ochoa 
AC, Garber JE, Zimbler H, Armstrong DK, Tkaczuk KHR, Riseberg DA, O'Connor BM, 
Openshaw TH, Zakalik D, Vakhariya CM, Schott AF, Simon MS, Doyle TJ, Yost KJ, 
Flynn PJ, Zera RT, Friday BEB, Ruddy KJ, Steen PD, Ademuyiwa FO, Levine EA, 
Marcom PK, Harkness CB, Tan AR, Charles WJ, Kuzma CS, Radford JE, Atkins JN, 
Unnikrishnan M, Seeger GR, Leu KMH, Copur MS, Hauke RJ, Soori GS, Arrick BA, 
Reeder JG, Toppmeyer DL, Dayao ZR, Adams S, Cigler T, Barr PM, Anampa Mesias 
JDS, Weiselberg LR, Ramaswamy B, Gerds AT, Shenk RR, Gross HM, Trehan S, Razaq 
W, Mansoor AH, Julian TB, Brufsky AM, Boyle LE, Chowdhury N, DeNittis AS, 
Domchek SM, Obeid E, Cescon TP, Rovito MA, Vogel VG, Baez-Diaz L, Brescia FJ, 
Doster JE, Siegel RD, Wong L, Patel T, Nangia JR, Jones CA, Cannon GM, Bear HD, 
Harnden KK, Wood ME, Alluri KC, Bridges BB, Specht JM, Qamar R, Ryan ML, Gayle 
AA, Jubelirer SJ, Kurian S, Salkeni MA, Silander G, Hallbeck AL, von Wachenfeldt 
Väppling A, Curtit E, Cardoso C, Braga S, Abreu M, Casa-Nova M, Nave M, Ciruelos 
Gil EM, Gelpi JB, Fernández Ortega A, Gumà Padró J, Bermejo de Las Heras B, 
González Cao M, Cueva Bañuelos J, Company JA, Viñas Villaró G, García Estevez L, 
Huober J, Busch S, Fehm T, Baden-Baden S, Hahn A, Grafe A, Noesselt T, Dewitz T, 
Wagner H, Bechtner C, Weigel M, Kolberg HC, Decker T, Thomalla J, Hesse T, 
Harbeck N, Schröder J, Blohmer JU, Sütterlin MW, Altena R, Chiu CF, Chen SC, Hou 
MF, Chang YC, Chen SH, Chen ST, Huang CS, Yeh DC, Yu JC, Tseng LM, Chung WP, 
Mailliez A, Petit T, Lévy C, Dalivoust P, Extra JM, Mouret-Reynier MA, 
Hardy-Bessard AC, Simon H, L'Haridon T, Mege A, Giacchetti S, Chakiba-Brugere C, 
Gratet A, Pottier V, Ferrero JM, Tennevet I, Perrin C, Canon JL, Joris S, Shao 
Z, Xu B, Jiang Z, Sun Q, Shen K, Pang D, Zhang J, Wang S, Yang H, Liao N, Zheng 
H, Fu P, Song C, Wang Y, Fan Z, Geng C, Tredan O, Landherr L, Yerushalmi R, 
Uziely B, Conte P, Zamagni C, Bianchini G, De Laurentiis M, Tondini C, Gebbia V, 
Ciccarese M, Sarosiek T, Mackiewicz J, Słowińska A, Kalinka E, Huzarski T, Jung 
KH, Sohn JH, Kim JH, Lee KS, Park YH, Lee KE, Chae YS, Cho EK.

Author information:
(1)From the Breast Cancer Now Toby Robins Research Centre, the Institute of 
Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital 
Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge 
(S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) 
- all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical 
School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. 
Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology 
Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel 
(B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan 
(G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, 
l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., 
H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson 
Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC 
Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics 
(H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), 
Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the 
National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron 
Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in 
Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University 
Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, 
Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; 
the Department of Oncology and Radiotherapy, Medical University of Gdańsk, 
Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of 
Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian 
Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in 
Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA 
Fielding School of Public Health, David Geffen School of Medicine at UCLA 
(P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles 
- all in California; Fudan University Shanghai Cancer Center, Shanghai, China, 
(Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and 
Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, 
Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe 
University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian 
Cancer and the Center for Integrated Oncology, Faculty of Medicine, University 
Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal 
Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, 
Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland 
Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in 
Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill 
Cornell Medical College (C.E.G.) - both in Houston.

Comment in
    Nat Rev Clin Oncol. 2021 Oct;18(10):607-608. doi: 
10.1038/s41571-021-00544-7.
    N Engl J Med. 2021 Oct 7;385(15):1439. doi: 10.1056/NEJMc2112373.
    N Engl J Med. 2021 Oct 7;385(15):1439-1440. doi: 10.1056/NEJMc2112373.

BACKGROUND: Poly(adenosine diphosphate-ribose) polymerase inhibitors target 
cancers with defects in homologous recombination repair by synthetic lethality. 
New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 
germline mutation-associated early breast cancer.
METHODS: We conducted a phase 3, double-blind, randomized trial involving 
patients with human epidermal growth factor receptor 2 (HER2)-negative early 
breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic 
variants and high-risk clinicopathological factors who had received local 
treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomly 
assigned (in a 1:1 ratio) to 1 year of oral olaparib or placebo. The primary end 
point was invasive disease-free survival.
RESULTS: A total of 1836 patients underwent randomization. At a prespecified 
event-driven interim analysis with a median follow-up of 2.5 years, the 3-year 
invasive disease-free survival was 85.9% in the olaparib group and 77.1% in the 
placebo group (difference, 8.8 percentage points; 95% confidence interval [CI], 
4.5 to 13.0; hazard ratio for invasive disease or death, 0.58; 99.5% CI, 0.41 to 
0.82; P<0.001). The 3-year distant disease-free survival was 87.5% in the 
olaparib group and 80.4% in the placebo group (difference, 7.1 percentage 
points; 95% CI, 3.0 to 11.1; hazard ratio for distant disease or death, 0.57; 
99.5% CI, 0.39 to 0.83; P<0.001). Olaparib was associated with fewer deaths than 
placebo (59 and 86, respectively) (hazard ratio, 0.68; 99% CI, 0.44 to 1.05; 
P = 0.02); however, the between-group difference was not significant at an 
interim-analysis boundary of a P value of less than 0.01. Safety data were 
consistent with known side effects of olaparib, with no excess serious adverse 
events or adverse events of special interest.
CONCLUSIONS: Among patients with high-risk, HER2-negative early breast cancer 
and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant 
olaparib after completion of local treatment and neoadjuvant or adjuvant 
chemotherapy was associated with significantly longer survival free of invasive 
or distant disease than was placebo. Olaparib had limited effects on global 
patient-reported quality of life. (Funded by the National Cancer Institute and 
AstraZeneca; OlympiA ClinicalTrials.gov number, NCT02032823.).

Copyright © 2021 Massachusetts Medical Society.

DOI: 10.1056/NEJMoa2105215
PMCID: PMC9126186
PMID: 34081848 [Indexed for MEDLINE]